Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer
Effectiveness of Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer
Dharmais National Cancer Center Hospital
136 participants
Mar 18, 2024
INTERVENTIONAL
Conditions
Summary
This study aims to evaluate the effectiveness of the Lymphovenous Bypass (LVB) procedure compared to physiotherapy alone as secondary prevention of lymphedema in breast cancer patients undergoing axillary lymph node dissection.
Eligibility
Inclusion Criteria3
- Breast cancer patients aged ≥ 18 years with an ECOG score \> 1
- Breast cancer patients with post-axillary lymph node dissection diagnosed with stage 0 and I lymphedema.
- Those who have never undergone lymphedema physiotherapy.
Exclusion Criteria3
- Patients with dermal backflow before axillary lymph node dissection (ALND).
- Patients with breast cancer lymphedema who are unable to undergo a 24-month follow-up at Dharmais Cancer Hospital.
- Patients with iodine allergy, severe asthma, decreased kidney function, pregnancy, or breastfeeding.
Interventions
The Lymphovenous Bypass (LVB) procedure in this study is a microsurgical supermicrosurgery-based intervention specifically designed for the secondary prevention of breast cancer-related lymphedema following axillary lymph node dissection.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07233863